Renal Denervation Market Top Companies Analysis To Grow Your Business by 2026

Contact Us
Tejashri Khade
121/7E Avenue Franklin Roosevelt 1050 Brussels
Brussels
Brussels 1050 
Belgium
Phone:+ 32 498 86 80 79
tejashri.k@meditechinsights.com

Approximately 12-15% of the population treated for high blood pressure suffers from resistant hypertension. Renal denervation is a minimally invasive procedure for the treatment of resistant hypertension. As the geriatric population is increasing, the number of people suffering from hypertension and the resistant hypertension is also growing which fueling the growth of the RDN market.

The Global Renal Denervation (RDN) Market is estimated at $140 Million (2022) growing at a CAGR of 40%. The market growth is driven by the growing geriatric population, the increasing prevalence of hypertension, and venture capital funding. The U.S. market is likely to offer high growth opportunities over the next 3-5 years.

Rising Prevalence of Hypertension is driving the Growth of the Renal Denervation Market
According to WHO, as of now more than one billion individuals worldwide suffer from hypertension which is expected to grow to 1.6 billion by 2025. WHO assessed that less than one in five people have their hypertension under control, either due to non-adherence or resistance to medication. This is leading to an increasing prevalence of hypertension/resistant hypertension, thus driving the growth of the renal denervation market.

Absence of long-term clinical data and risks associated with RDN procedures fuels the Renal Denervation Market Growth
Though Renal Denervation is perceived as a potential treatment for resistant hypertension, it is a generally new methodology and less data is available on its long-term effects. Due to the limited clinical evidence, the RDN products are available only for investigational purpose in some of the major markets.

For instance,

The use of Medtronic’s Symplicity Spyral RDN System in the U.S., Japan and Canada is limited to investigational purpose. In addition, there are several risks associated with this procedure which limits its applications. Bradycardia occurs in some patients during the procedure.

The RF ablation may cause changes to the wall of the arteries, which can sometimes lead to renal artery stenosis. The imaging used throughout the procedure also has a number of risks. Other difficulties include tearing in the renal arteries and pseudoaneurysm (a bruise caused by a leaking hole in an artery).

Explore Premium Report on Global Renal Denervation (RDN) Market @ https://meditechinsights.com/global-renal-denervation-market/

North America to offer significant growth opportunities in Renal Denervation Market
According to a geographic point of view, Europe is the single biggest renal denervation market. This is mostly attributed to the increasing aging population, rising prevalence of hypertension, and higher penetration because of commercial availability of RDN products inside Europe. The North American market is at nascent stage as the RDN organizations are yet to launch the products for commercial use in the region. Though, the companies operating in the renal denervation market are flourishing to present their products in the U.S. market and are concentrating their efforts on getting the commercial approvals.

For instance,

Medtronic is likely to publish its results of SPYRAL HTN-ON MED clinical trials for its RDN system in the U.S. in later half of 2022.
Further, in March 2022, ReCor Medical (Otsuka) completed subject enrolment for its RADIANCE-II pivotal trial of its Paradise Ultrasound Renal Denervation (uRDN) System for generating clinical trial data to enter the U.S. renal denervation market.

Citing the growth potential of Renal Denervation market, venture capital firms are helping start-ups to expedite their clinical trial efforts
In December 2021, SyMap Medical completed financing round of $100 million led by Primavera Capital and VMS Group, with the participation of existing investors Simiao Equity Investment and Sequoia Capital China.

In April 2021, China-based renal denervation firm Brattea completed $20 million funding round. The round was led by led by healthcare private equity fund Kuanping Capital.

Competitive Landscape Analysis of Renal Denervation (RDN) Market
Some topmost industry players operating in the global renal denervation market are Medtronic, Boston Scientific Corporation, St. Jude Medical (Abbott), ReCor Medical (Otsuka), and Terumo Corporation, among others.

For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights:
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact Us:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com